Verification evidence is still being completed.
PDF / print export
Zealand Pharma
Copenhagen, Denmark
- Verified lead
- Adam Steensberg
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- President and Chief Executive Officer
- 2026 technical specialization
- Peptide Therapeutics
- Review cycle
- May 2026
- Full address
- Professional N/A
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official Zealand Pharma management page confirming Adam Steensberg as President and CEO.
- Editorial note
- Zealand remains a strong verified profile with current corporate management confirming Adam Steensberg as the operating lead.
Peptide Therapeutics
Clinical Phase III
Zealand remains a strong verified profile with current corporate management confirming Adam Steensberg as the operating lead.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated05 Jun 2026, 01:06
Company profile · Copenhagen, Denmark
Zealand Pharma
Peptide Therapeutics · Global Biopharma
Verified 14 Mar 2026 · 3 sources
Clinical
Zealand remains a strong verified profile with current corporate management confirming Adam Steensberg as the operating lead.
Contact & location
- Website
- zealandpharma.com
- Company page
- Lead
- Adam Steensberg (verified ↗)
- Compliance
- FDA-Inspected
- Last reviewed
- 14 Mar 2026 (3mo ago)
- Scale
- Global Biopharma
- Capabilities
- Peptide Engineering · Metabolic Research · GI Disease Therapy
- Founded
- 1998
- Headcount
- 201-500
Clinical profileSTATUS: VERIFIED MARCH 2026
Adam Steensberg
President and Chief Executive Officer
Full addressProfessional N/A
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Global Biopharma
Copenhagen, Denmark. Peptide Therapeutics. Review completed on 14 Mar 2026.
DKMA / EMA
Clinical Phase III
Peptide Therapeutics
Zealand remains a strong verified profile with current corporate management confirming Adam Steensberg as the operating lead.
Editorial note
Zealand remains a strong verified profile with current corporate management confirming Adam Steensberg as the operating lead.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Peptide Engineering
Metabolic Research
GI Disease Therapy
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Mass Spec Hub
Peptide Synthesis skids
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- VERIFIED ACTIVE 2026
Verification history
Verification history
14 Mar 2026: Executive identity confirmed via official management disclosure.
14 Mar 2026: Trust review remains in progress.
FAQ
Frequently asked questions
- Where is Zealand Pharma located?
- Zealand Pharma is based in Copenhagen, Denmark.
- Who runs Zealand Pharma?
- Zealand Pharma is led by Adam Steensberg, President and Chief Executive Officer. Verified 14 Mar 2026.
- What does Zealand Pharma do?
- Zealand remains a strong verified profile with current corporate management confirming Adam Steensberg as the operating lead. Core capabilities: Peptide Engineering, Metabolic Research, GI Disease Therapy.
Editorial context
Related technical briefs
Briefs that name Copenhagen as a covered market or city.